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Background: Many case series have been published on treatments of varicose veins, but comparative randomized
controlled trials remain sparse.
Objective: To compare the anatomic success rate, frequency of major complications, and quality-of-life improvement of
endovenous laser ablation (EVLA), ultrasound-guided foam sclerotherapy (UGFS), and conventional surgery (CS), after
1-year follow-up.
Methods: A total of 240 consecutive patients with primary symptomatic great saphenous vein reﬂux were randomized to
EVLA, UGFS, or CS, consisting of high ligation and short stripping. Primary outcome was anatomic success deﬁned as
obliteration or absence of the treated vein on ultrasound examination after 1 year. Secondary outcomes were compli-
cations, improvement of the “C” class of the CEAP classiﬁcation, and improvement of disease-speciﬁc (Chronic Venous
Insufﬁciency Quality-of-Life Questionnaire) and general (EuroQol 5) quality-of-life scores.
Results: More than 80% of the study population was classiﬁed as C2 or C3 venous disease. After 1 year, the anatomic
success rate was highest after EVLA (88.5%), followed by CS (88.2%) and UGFS (72.2%) (P < .001). The complication
rate was low and comparable between treatment groups. All groups showed signiﬁcant (P < .001) improvement of
EuroQol 5 and Chronic Venous Insufﬁciency Quality-of-Life Questionnaire scores after therapy; 84.3% of all treated
patients showed an improvement of the “C” of the CEAP classiﬁcation.
Conclusions: After 1-year follow-up, EVLA is as effective as CS and superior to UGFS according to occlusion on ultra-
sound duplex. Quality of life improves after treatment in all groups signiﬁcantly. (J Vasc Surg 2013;58:727-34.)Varicose veins of the legs affect approximately 25%
of the population1 and may have a substantial impact
on patient’s health-related quality of life (HRQoL). The
treatment of varicose veins and its complications consume
a relatively large proportion of the limited health care
resources.1,2 Until recently, conventional surgery (CS) of
the great saphenous vein (GSV), consisting of high ligation
at the saphenofemoral junction (SFJ) and stripping of the
above knee GSV, was the standard of care. In the last
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://dx.doi.org/10.1016/j.jvs.2012.12.074laser ablation (EVLA), radiofrequency ablation (RFA), and
ultrasound-guided foam sclerotherapy (UGFS) have chal-
lenged the position of CS for primary varicose veins.3
These techniques are effective (occlusion rates of EVLA
and RFA >90%) and safe.4,5 CS associates stripping of
the reﬂuxing GSV trunk with high ligation at the SFJ,
and this may induce neovascularization.6-8 Endovenous
treatment techniques are performed without high ligation,
which may be an advantage. Additional advantages of
EVLA, RFA, and UGFS over CS are that they can be easily
performed in an ambulatory setting. A comparative meta-
analysis of observational studies and randomized clinical
trials (RCTs) demonstrated that both EVLA and RFA
were superior to CS and UGFS.5 In the last few years,
several important RCTs comparing two different treatment
modalities for varicose veins show that the minimally inva-
sive techniques are at least as effective as CS and that they
result in faster recovery time and less postoperative pain,
and they are preferred by patients.7-11 In 2011, Rasmussen
et al were the ﬁrst to compare more than two different
treatments in a four-arm RCT.12 This study showed that
thermal ablation and CS, all performed under tumescent
anesthesia, had better anatomic results than UGFS;
however, patient-reported outcomes were better after in
the UGFS and RFA.
A recent comparative study of UGFS and CS showed
signiﬁcantly higher efﬁcacy rates 2 years after CS. However,
there were no differences in patient-reported outcomes.13727
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success rate, frequency of complications, and HRQoL
improvement of EVLA, UGFS, and CS for the treatment
of primary incompetent GSV after 1 year.
METHODS
Our study was designed as a consecutive single-center
RCT at the Departments of Dermatology and Vascular
Surgery of Erasmus Medical Center Rotterdam, The
Netherlands, starting in January 2007. Because of a
decreasing inclusion rate, the same departments of Cathar-
ina Hospital Eindhoven were added as second center in
May 2009. The last patient was treated in May 2010. The
medical ethics committee of Erasmus Medical Center,
Rotterdam approved our protocol (MEC2005-325).
In Latin, the GSV is called “vena saphena magna” and
in The Netherlands, we use this name to indicate the GSV;
therefore, we have chosen to call our study the MAGNA
trial.
Adult patients with a symptomatic primary incompe-
tent GSV at least above the knee with a diameter of
$0.5 cm and with an incompetent SFJ were eligible to
participate. The incompetence of the GSV was deﬁned as
reﬂux of $0.5 seconds at color duplex ultrasound (HDI
4500, 10-MHz probe; Philips, Andover, Mass). Exclusion
criteria were previous treatment of the ipsilateral GSV,
deep venous incompetence or obstruction, agenesis of the
deep system, vascular malformations, use of anticoagula-
tion, pregnancy, heart failure, contraindication for one of
the treatments, (eg, allergy for aethoxysclerol or lidocaine),
immobility, arterial insufﬁciency (deﬁned as an ankle-
brachial index <0.6), age under 18 years, and inability to
provide written informed consent to trial participation.
Treatment. In this study, only the GSV in the thigh
(from just below or above knee level in most cases) was
treated. Patients were allocated to one of the three treat-
ments. After written informed consent, eligible patients
were randomized using a computerized list by an indepen-
dent research nurse. All treatments were performed by
dermatologists or surgeons with more than 5 years of
experience with the treatments (EVLA and UGFS, and
CS and EVLA, respectively).
EVLA. EVLA was performed under ultrasound guid-
ance with a 940-nm diode laser as previously described.14
In brief, venous access was obtained by puncturing the
vein at knee level, with a 16 or 18F needle under ultra-
sound guidance. After entrance to the varicose vein was
established, a guidewire was passed through the hollow
needle into the vein up to the level of the SFJ. The needle
was removed and a small cutaneous incision of 3 mm was
made; then, an introducer sheath was passed over the
guidewire. Subsequently, the laser ﬁber was introduced
after removing the guidewire. The laser ﬁber was posi-
tioned 1-2 cm below the SFJ. About 250-500 mL
(depending on the length of treated vein) of tumescent
anesthetic solution was administered into the saphenous
compartment under ultrasound guidance using a mechan-
ical infusion pump. Withdrawal of the laser ﬁber wasperformed in continuous mode, and it was attempted to
deliver at least 60 J/cm.15
UGFS. Ultrasound-guided foam sclerotherapy was
performed as reported previously.14 The Tessari-method16
was used to prepare foam (1 cc aethoxysclerol 3%: 3 cc
air), which was injected directly under ultrasound guidance
in the GSV with the patient in a horizontal position.14,16
The volume of injected foam depended on the length and
diameter of the vessel, with amaximumof 10mL per session
(as suggested by the Second European Consensus).17 After
injection, the patient remained in a prone position for at
least 5 minutes. If considered necessary, UGFS of the
included GSV could be repeated after 3 months.
CS. High ligation with short (above knee) stripping
was performed under spinal or general anesthesia. Flush
SFJ ligation was followed by ligation of all tributaries
back to the second branch and invaginating stripping of
the GSV to knee level. The cribriform fascia, superﬁcial
fascia, and skin were closed.
After all treatments, an ambulatory compressive
bandage was applied for 48 hours, followed by therapeutic
compression stockings for 2 weeks postprocedure. All
patients were observed for at least one-half of an hour in
the clinic after treatment. No speciﬁc analgesics were
prescribed. Patients were encouraged to mobilize and to
resume their usual activities as soon as possible.
Outcomes
Primary outcome. Patients were evaluated at 3 and
12 months for clinical examination and duplex ultrasound.
The primary outcome was anatomic success according to
duplex ultrasound evaluation. For EVLA and UGFS, this
was deﬁned as complete obliteration, without ﬂow or
reﬂux, of the GSV at the level of the midthigh. For CS,
success was deﬁned as absence of the GSV in the saphenous
compartment at thigh level. We differentiated between
obliteration, partial, or complete patency of the treated
vein, with or without reﬂux.
Postoperative neovascularization was assessed at the
level of the SFJ using the classiﬁcation described by De
Maeseneer et al. They state that “The degree of neovascu-
larization was determined as ‘grade 1 neovascularization’
(tiny new vein(s) up to 3 mm diameter, not connecting
with any superﬁcial vein) and ‘grade 2 neovascularization’
(tortuous new vein[s] with a diameter $4 mm, with path-
ological reﬂux and connecting with thigh varicose
veins).”18
Secondary outcomes. At all visits, the “C” of the
CEAP classiﬁcation was recorded. The basic CEAP classiﬁ-
cation as described by Eklöf was used, which means
patients are classiﬁed according to their highest C score.19
The type and frequency of complications of the different
treatments were reported. The following complications
were assessed: superﬁcial vein thrombosis (related to site of
treatment), hyperpigmentation (at treatment site), pares-
thesia (deﬁned as abnormal skin sensations such as tingling,
tickling, itching, burning, or numbness), scotoma,
migraine, skin burns, skin necrosis, anaphylactic shock,
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symptomatic deep venous thrombosis (DVT), based on
history and conﬁrmed by duplex examination, and symp-
tomatic pulmonary embolism.
The effect of the treatment on HRQoL was assessed
using the disease-speciﬁc Chronic Venous Insufﬁciency
Quality-of-Life Questionnaire (CIVIQ)20 and the generic
EuroQol 5D (EQ-5D) instrument21 questionnaire. Health
is a supplement of the EQ-5D. Patients can indicate on
a visual analog scale what number they give at their general
health. Additional phlebectomies performed during CS or
EVLA of GSV or 3 months postoperative were noted.
UGFS could be repeated after initial study treatment or
could be used as an “escape” therapy in case of failure of
the initially allocated treatment.
Statistical analysis. Sample size calculation indicated
that 240 legs (80 in each group) were needed to detect
a 10% difference in the proportion of patients with occlu-
sion after 1 year between EVLA and UGFS and a 20%
difference between EVLA and CS with a power of 90%
and an alpha level of P < .05.
Data were analyzed on an intention-to-treat basis.
Continuous data were ﬁrst tested for normality using
one-sample Kolmogorov-Smirnov Test. For normal distri-
bution, data were presented as means with standard devi-
ations (SDs), and analysis with one-way analysis of
variance was done to compare it across three treatment
groups.
Categorical data were analyzed by means of c2 test or,
if appropriate, Fisher exact test. To gauge whether the
treatment-related difference in CIVIQ scores was clinically
relevant, we used Norman’s rule of thumb when the
change in score was more than one-half an SD of the distri-
bution of the CIVIQ score prior to therapy, the change
was considered clinically meaningful.22 Patients with bilat-
eral GSV insufﬁciency were randomized separately for each
leg. For efﬁcacy analysis, both GSVs were included, but for
HRQoL analyses, these patients were excluded because
patients are unable to differentiate the impact of varicose
veins of each leg on HRQoL.23
A generalized estimating equation model with a logit
link was used to model the odds ratio for total occlusion
over time. To take the correlation into account between
two legs of the same patient and multiple measurements
over time, we chose an unstructured covariance matrix
and used the patients as the independent subjects. For
EQ-5D, CIVIQ, Health, and CEAP outcomes, we used
a linear mixed model with empirical standard errors. For
this model, we chose a direct product of an unstructured
covariance matrix (for the covariance within a leg) and
a compound symmetry correlation matrix (for the correla-
tions within a patient between the legs). Thereby, we allow
for an unstructured correlation matrix between measure-
ments over time within one leg, and we assume that the
unstructured correlation matrix is equal for the ﬁrst and
the second leg within one person.
Statistical analysis was performed using SPSS v. 20.0
(SPSS Inc, Chicago, Ill) and SAS 9.2 (SAS Institute,Cary, NC). All statistical tests were two-sided and consid-
ered signiﬁcant at the P < .05 level.
RESULTS
Study population. In 223 eligible patients, 240 legs
were randomized for one of the treatments between
January 2007 and December 2009 (Fig 1). Seventeen
patients were excluded from the analysis; 16 did not fulﬁll
the inclusion criteria and one was lost to follow-up.
Five patients were treated with UGFS because initial
treatment had failed: two patients from the EVLA group
and three patients from the CS group. Data were analyzed
on an “intention-to-treat” basis, according to randomiza-
tion. “As-treated” analysis showed no signiﬁcant difference
from the intention-to-treat analysis.
In the study population, 82.3% suffered C2 and/or C3
venous insufﬁciency. The groups were well matched for the
demographic data, CEAP classiﬁcation, and GSV diameter
and HRQoL impairment (Table I). The patients in the
EVLA group were signiﬁcantly younger than those in the
CS and UGFS group. Patients in the EVLA group received
on average 59.16 J/cm (SD, 15.20). Patients in the UGFS
group received a mean of 4.7 cc (SD, 1.19) foam. The
majority of patients were treated in one session of UGFS.
Six patients with lasting complaints received a second
treatment within the ﬁrst year.
Anatomic success. EVLA and surgery were compa-
rably effective (88.5%, n ¼ 69; 88.2%, n¼ 60, respectively),
after 1-year follow-up (Fig 2). However, in the CS group,
10% (n ¼ 7) of patients had grade 1 neovascularization at
ultrasound examination of the groin. After 1 year, the
occlusion rate of UGFS was 72.7% (n ¼ 56), which was
signiﬁcantly lower than EVLA and CS (P < .02). Twenty-
one patients (27.3%) of the UGFS group had partial oblit-
eration with reﬂux. In 11 of these patients, initial treatment
resulted in complete relief of complaints despite persisting
reﬂux after 1-year follow-up, and therefore they did not
undergo any additional treatment.
Clinical improvement. In all groups, the C of the
CEAP-classiﬁcation decreased signiﬁcantly after treatment,
and there was no difference between groups. An improve-
ment of the C score was seen in 79.4% of all treated patients
at 3 months (Fig 3; Supplementary Table, online only).
After 12months, 47.6% of all patients showed improvement
of at least two categories (Table II). However, the mean
improvement in C score was not signiﬁcantly different
between the three groups. The clinical situation according
to the CEAP deteriorated in one patient treated with
EVLA; he developed hyperpigmentation at the treatment
site and ankle after treatment.
Complications. Complications were recorded in the
ﬁrst year after initial treatment (Table III). The frequency
of adverse events was low and not signiﬁcantly different
between the three treatment groups (P ¼ .64). Ten
patients were seen earlier than 3 months after treatment
with complaints of pain. All these patients had a superﬁcial
vein thrombosis of a tributary of the GSV, and duplex
ultrasound excluded additional DVT in all cases. No
Randomized 
n = 240 
Enrollment
Allocation 
Allocated to EVLA n = 80 
Underwent intervention n = 76 
Procedure failure n = 2a
Other intervention n = 1b
No intervention n = 1b
Allocated to UGFS n = 80 
Underwent intervention 
n = 77 
Procedure failure n = 0 
Other intervention n = 2b
Allocated to surgery n = 80 
Underwent intervention n = 65 
Procedure failure n = 3a
Other intervention n = 4b
No intervention n = 8b
Follow-up  Lost of follow-up n = 0 
Death n = 0 
Lost of follow-up n = 1b
Death n = 0 
Lost of follow-up n = 0 
Death n = 0 
Analysis 
Analyzed:  68 Analyzed: 77 Analyzed: 78 
Fig 1. Consort ﬂow. aIf there was a procedure failure, patients were treated with ultrasound-guided foam sclerotherapy
(UGFS), and data analysis was on an intention-to-treat basis. bPatients who did not receive treatment or received
another treatment or were lost to follow-up in the ﬁrst year were excluded from the analysis. EVLA, Endovenous laser
ablation.
Table I. The distribution of baseline characteristics for each of the three treatment groups
EVLA (n ¼ 78) UGFS (n ¼ 77) CS (n ¼ 68) P value
Age, years (SD) 49 (15.03) 56 (13.30) 52 (15.59) .005a
Sex, No. (%)
Women 54 (69.2) 52 (67.5) 46 (67.6) .89b
Men 24 (30.8) 25 (32.5) 22 (32.4)
Side, No. (%)
Left 48 (61.5) 45 (58.4) 34 (50) .36b
Right 30 (38.5) 32 (41.6) 34 (50)
Unilateral, No. (%) 62 (79.5) 58 (75.3) 51 (75) .74b
Bilateral (same treatment) 6 (7.7) 11 (14.3) 8 (11.7)
Bilateral (different treatment) 10 (12.8) 8 (10.4) 9 (13.3)
Mean GSV diameter
Left, cm (SD) 0.64 ( 0.15) 0.58 (0.14) 0.62 (0.14) .08a
Right, cm (SD) 0.59 (0.11) 0.62 (0.14) 0.59(0.16) .65a
CEAP, No. (%)
C1 0 0 0 .64c
C2 37 (47.4) 33 (42.9) 28 (41.2)
C3 29 (37.2) 30 (39.0) 21 (30.9)
C4 8 (10.3) 8 (10.4) 14 (20.6)
C5 0 1 (1.3) 1 (1.5)
C6 0 0 0
Unknown 4 (5.1) 5 (6.5) 4 (5.8)
CIVIQ
Mean score (SD) 25.21 (20.73) 23.96 (17.97) 25.13 (19.15) .91a
EQ-5D
Mean score (SD) 0.85 (0.16) 0.83 (0.20) 0.86 (0.11) .65a
General health score, % (SD) 79.4 (14.6) 78.8 (12.5) 79.1 (12.7) .96a
CIVIQ , Chronic Venous Insufﬁciency Quality-of-Life Questionnaire; CS, conventional surgery; EQ-5D, EuroQol 5D; EVLA, endovenous laser ablation;
GSV, great saphenous vein; IQR, interquartile range; SD, standard deviation; UGFS, ultrasound-guided foam sclerotherapy.
aAnalysis of variance.
bc2.
cFisher exact.
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occurred. No procedure-related mortality was observed.
Three patients received antibiotics because of wound
infection in the groin after CS; there were no woundinfections after EVLA nor after UGFS (P ¼ .023). Most of
the milder adverse events were transient and disappeared
after 3 months. Overall, 11 CS, seven EVLA, and ﬁve
UGFS patients reported any adverse events.
Fig 2. Complete obliteration after 12 months. The proportion of
legs that had complete obliteration or absence of the great saphe-
nous vein (GSV) after treatment was signiﬁcantly different between
endovenous laser ablation (EVLA), ultrasound-guided foam
sclerotherapy (UGFS), and conventional surgery (CS) (P < .02).
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insufﬁciency were excluded from all QoL analysis. Eight of
these patients were allocated for the same treatment in
both legs and nine patients for different treatments.
The CIVIQ and EQ-5D score improved in all groups at
3 months and remained relatively stable until 1 year (Fig 3,
B-D; Supplementary Table, online only) CIVIQ score and
EQ-5D showed no signiﬁcant differences between the
three groups. Additional analysis adjusted for age and sex
showed no signiﬁcant differences for CIVIQ, EQ-5D, and
Health score.
It is remarkable that the CIVIQ scores improved in
11 patients (14%) of the UGFS group despite their remain-
ing (segmental) reﬂux on ultrasound examination and
without performing additional injections.
Additional interventions. Phlebectomies were per-
mitted during initial treatment with the intention of
removing all varicosities in the same procedure, but
because of practical issues, this was not possible in all cases.
In 15 patients (19.2%) in the EVLA group and 18 (25.7%)
in the CS group, phlebectomy was performed during initial
treatment. In 12 (15.3%), 15 (19.5%), and 11 (15.7%) of
the EVLA, UGFS, and CS group respectively, phlebecto-
mies were performed after 3 months. In the UGFS group,
six patients (4.6%) with lasting reﬂux and complaints
received a second injection with foam.
Subgroup analysis. Subgroup analysis did not show
any signiﬁcant differences between anatomic success, clin-
ical improvement, complications, or quality of life improve-
ments between the two centers.
There were no signiﬁcant differences of CIVIQ and
EQ-5D scores between unilateral and bilateral treatments
(n ¼ 52) nor between groups with or without additional
treatments. There were no signiﬁcant differences in
anatomic success, CEAP classiﬁcation, or HRQoL scores
between patients who received additional treatments andthose who did not. The group that received additional
treatments reported more adverse events than the patients
who had only GSV treatment (12.7% vs 6.7%; P ¼ .228).
DISCUSSION
In the last decade, EVLA and RFA were introduced and
UGFS has been optimized. These minimal invasive inter-
ventions are increasingly used as an alternative to CS for
treating saphenous veins.4,5 The MAGNA trial shows that
EVLA and CS are comparably effective (almost 90%) and
that both are signiﬁcantly more effective than UGFS
(72.7%) using ultrasound-based anatomic outcomes.
Complications are rare and quality of life (CIVIQ and
EQ-5D) improved after each treatment. Using a repeated-
measure analysis, there were no signiﬁcant differences in
CIVIQ and EQ-5D scores between the groups. Applying
the Norman’s rule of thumb on the unadjusted data, none
of the improvements in the CIVIQ and EQ-5D appeared
to be clinically relevant.22
The results of this RCT are strikingly similar to
other clinical studies, meta-analysis, and two recent RCTs
that included UGFS increasing the validity of the
ﬁndings.5,12,13,24 One year after treatment, remaining
(segmental) ﬂow with reﬂux was observed in more than
one-quarter of the patients treated with UGFS, which is in
line with other observational studies and RCTs.12,13,25,26
Neovascularization occurs in 10% of the patients in the CS
group 1 year postoperatively, which corresponds with
results of a previous study focusing on the effect of closing
the cribriform fascia to contain postoperative neovasculari-
zation at the SFJ.18
Despite randomization, EVLA-treated patients were
signiﬁcantly younger than those in the other two treatment
arms. Adjusting for age and sex in a logistic model, there
were no differences in CIVIQ scores or in CEAP classiﬁca-
tion between the three groups.
In accordance with other RCTs comparing CS to new
minimally invasive treatment methods, we had difﬁculty
enrolling the required number of patients in the RCT
because of the reluctance among patients to undergo
CS. Therefore, an additional center was added during
the study period. No differences in outcomes were noted
between the two centers. Of the 17 included patients that
withdrew from the trial, 10 were assigned to CS suggest-
ing that informed patients preferred minimally invasive
treatments.
The primary outcome of this study was total occlusion
and/or absence of the treated GSV according to ultra-
sound. This outcome has the advantage to be objective
and reproducible and is possibly a proxy of symptom reduc-
tion and future clinical relevant recurrence. These latter
assumptions will be tested when the 5-year results become
available. Also, deﬁning the outcome as total occlusion may
have been too strict, because “remodeling” of the insufﬁ-
cient vein, as is often seen after UGFS, may be associated
with alleviation of symptoms while persisting ﬂow with or
without reﬂux is present in the treated vein. Eleven patients
with residual reﬂux after UGFS did decline an additional
Fig 3. Repeated measurement analysis for CEAP and quality-of-life scores A, Thirteen patients with missing CEAP
scores were excluded. B, Fourteen patients with missing Chronic Venous Insufﬁciency Quality-of-Life Questionnaire
(CIVIQ) scores and 24 patients with different bilateral randomized treatment were excluded. C and D, Twenty-four
patients with missing EuroQol 5D (EQ-5D)/health scores and 24 patients with different bilateral randomized treat-
ment were excluded. CS, Conventional surgery; EVLA, endovenous laser ablation; UGFS, ultrasound-guided foam
sclerotherapy.
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This observation challenges the strict deﬁnition of primary
outcome criteria such as “total occlusion” and “absence of
reﬂux” used as the gold standard for evaluation after GSV
treatment in RCTs. Moreover, it emphasizes the convic-
tion that we treat patients and not ultrasound ﬁndings.27
Recently, the Union Internationale de Phlébologie has
proposed a new classiﬁcation to describe the fate of the
junction and the treated trunk after endovenous ablation.28
This classiﬁcation allows to describe postoperative ﬁndings
more detailed, distinguishing between obliteration, partial
or complete patency of the treated vein, and segmental
obliteration or patency of the treated trunk, with or
without reﬂux. Apart from these duplex ultrasound ﬁnd-
ings, clinical outcome parameters as well as other outcome
measures such as patient-reported outcomes (eg, HRQoL,symptoms, satisfaction, and preference) should be consid-
ered.13,28,29 In contrast to HRQoL, symptom reduction
was not maximally assessed in this study, which in retro-
spect is a missed opportunity.13 At time of the study
design, we overlooked the problem of including bilateral
GSV. For the HRQoL outcomes, patients with two
different study treatments were excluded from the HRQoL
analysis because patients may not differentiate HRQoL
impairment between both legs. Patients with the same
treatment for both legs were included for HRQoL analysis
by taking the correlation between HRQoL scores of the
same patient into account. All patients were included in
the efﬁcacy analysis, which was adjustment for bilateral
GSV treatments.
Because of the scarring after CS and in a lesser extent
EVLA having a blinded outcome assessor was not feasible.
Table II. Changes in “C” from CEAP classiﬁcation 12 months after therapy
C improvement
Total3.00 2.00 1.00 0 2.00
Type of treatment, No. (%)
EVLA 10 (13.5) 26 (35.1) 25 (33.8) 12 (16.2) 1 (0.4) 74
UGFS 7 (9.7) 22 (30.6) 33 (45.8) 10 (13.9) 0 72
CS 8 (12.5) 27 (42.2) 19 (29.7) 10 (15.6) 0 64
Total 25 (11.9) 75 (35.7) 77 (36.7) 32 (15.2) 1 (0.48) 210
CS, Conventional surgery; EVLA, endovenous laser ablation; UGFS, ultrasound-guided foam sclerotherapy.
Table III. Distribution of the complications for each of the three therapies at 3 and 12 months after therapy
EVLA (n ¼ 78) UGFS (n ¼ 77) CS (n ¼ 68) P valuea
3 months Hyperpigmentation 2 1 0 .78
Paresthesia 2 1 4 .30
Superﬁcial vein thrombosis 3 3 4 .85
Wound infectionb 0 0 3 .03
DVT 0 0 0 1.00
Pulmonary emboli 0 0 0 1.00
Death due to therapy 0 0 0 1.00
Total number of patients with complications 7 5 11 .64
12 months Hyperpigmentation 1 1 0 1.00
Paresthesia 0 1 1 1.00
CS, Conventional surgery; DVT, deep vein thrombosis; EVLA, endovenous laser ablation; UGFS, ultrasound-guided foam sclerotherapy.
aFisher exact.
bRequiring systemic antibiotics.
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necessarily part of the research team, hopefully limiting the
impact of this limitation.
In this study, phlebectomies were allowed during initial
treatment of the study, GSV in patients allocated to EVLA
or CS, or after 3 months for all included patients. Phlebecto-
mies were proposed to all study patients with residual superﬁ-
cial varicose veins as additional treatment after 3 months
regardless of the study treatment. TheMAGNA trial includes
the three treatmentsmost frequently used inTheNetherlands
in 2007 explaining the exclusion of segmental RFA. In this
study, CS was performed using spinal or general anesthesia,
which is still common practice in TheNetherlands. It is antic-
ipated that the long-term results of the minimally invasive
interventions will stimulate surgeons to switch to minimally
invasive procedures and/or use of tumescent anesthesia
when CS is indicated.27 Using tumescent instead of general
anesthesia will improve patient satisfaction and will lead to
shorter down time after intervention.30 The 5-year follow-
up of the MAGNA trial and other similar ongoing RCTs
will further clarify whether the observed results of EVLA,
UGFS, and CS persist over time.
CONCLUSIONS
The 1-year results of the MAGNA trial show that the
short-term efﬁcacy, deﬁned as anatomic success according
to duplex ultrasound, is equally high for EVLA and CS
and lower for UGFS. The treatments are equally safe; no
severe adverse events were seen. Wound infections andneovascularization were more common after CS. All thera-
pies resulted in signiﬁcant clinical and HRQoL improve-
ment. Long-term efﬁcacy of these three intervention
methods needs to be established and will be available in
4 years.
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Supplementary Table (online only). Repeated measurement analyses for all outcome measures
No. CS
EVLA UGFS
P valueOR for total occlusion 95% CI OR for total occlusion 95% CI
Anatomic success
Occlusion 223
Unadjusteda Reference 1.24 (0.56-2.77) 0.34 (0.17-0.67) .02
Adjusteda,b Reference 1.22 (0.55-2.69) 0.35 (0.17-0.67) .02
No.
Difference mean
change in score 95% CI
Difference mean
change in score 95% CI P value
CEAP
C score 210d
Unadjustedc Reference 0.00 (0.24 to 0.24) 0.09 (0.14 to 0.33) .61
Adjustedc,b Reference 0.00 (0.24 to 0.24) 0.10 (0.12 to 0.33) .55
Quality of life
CIVIQ 185e
Unadjustedc Reference 2.01 (6.43 to 2.41) 0.63 (4.91 to 3.65) .63
Adjustedc,b Reference 1.93 (6.36 to 2.49) 0.66 (4.89 to 3.57) .67
EQ-5D 175f
Unadjustedc Reference 0.01 (0.02 to 0.04) 0.01 (0.03 to 0.04) .86
Adjustedc,b Reference 0.01 (0.02 to 0.04) 0.01 (0.02 to 0.04) .81
Health 175f
Unadjustedc Reference 1.73 (e1.55 to 5.01) 2.03 (e4.79 to 0.73) .04
Adjustedc,b Reference 1.61 (1.67 to 4.89) 1.97 (4.78 to 0.84) .07
CI, Conﬁdence interval; CIVIQ, Chronic Venous Insufﬁciency Quality-of-Life Questionnaire; CS, conventional surgery; EQ-5D, EuroQol 5D; EVLA,
endovenous laser ablation; OR, odds ratio; UGFS, ultrasound-guided foam sclerotherapy.
aTime since randomization was included in the model.
bAdjusted for age and sex.
cTime since randomization and baseline score were included in the model.
dThirteen patients with missing CEAP scores at all time points were excluded.
eFourteen patients with missing CIVIQ scores and 24 patients with different bilateral randomized treatment were excluded.
fTwenty-four patients with missing EQ-5D/Health scores and 24 patients with different bilateral randomized treatment were excluded.
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